There are multiple mechanisms by which cells evade TGF-β-mediated growth inhibitory effects. In this report, we describe a novel mechanism by which cells become resistant to TGF- indicating involvement of active MEK1 in stabilizing TβRII. Collectively, our data suggest a novel mechanism for MEK1 in regulating the sensitivity to TGF-β signaling by stabilizing TβRII.
INTRODUCTION
TGF-β signaling affects numerous cellular processes, including proliferation, differentiation, migration and apoptosis, depending on the cell type and its stage in malignant progression (1, 2) . TGF-β initiates signaling by binding to and bringing together type I (TβRI) and type II (TβRII) receptor serine/threonine kinases on the cell surface (3) . This allows receptor II to phosphorylate the receptor I kinase domain, which then propagates the signal through phosphorylation of the receptor-regulated Smad protein (Smad2/3), which is directly phosphorylated and activated by the type I receptor kinase. It then undergoes homotrimerization and formation of heteromeric complexes with a common partner, Smad4.
The activated Smad complexes translocate into the nucleus and, in conjunction with other nuclear cofactors, regulate the transcription of target genes. The Smad pathway is negatively regulated by Inhibitory Smad (Smad6/7) (4, 5) and PPM1A phosphatase (6) .
Low expression levels of TβRII were found in human B cell lymphoma cell lines (7) and breast cancers (8) , and were thought to be responsible for the development of resistance to TGF-β-induced growth arrest.
Mutations in the TβRII were also found in colon and gastric cancer with microsatellite instability (MSI) (9, 10) . TβRII frameshift mutations have been found in human gliomas (11) . TβRII missense mutations have been observed in two head and neck carcinoma cell lines (12) . TGF-β receptor expression may also be reduced in tumor cells through hypermethylation of CpG islands in the TβRII gene promoters (13) , or from mutations in the TβRII promoter that interfere with transcription factor binding (14) . The oncogene EWSR1 can repress TβRII expression by blocking TβRII promoter activity and may account for decreased responsiveness to TGF-β in some cancer cells (15) .
TβRs can interact with the pro-apoptotic adaptor protein Daxx (16) , TGF-β-activated kinase 1 (TAK1) (17) and Rho GTPase (18) , which lead to the induction of apoptosis or Epithelial/endothelialMesenchymal Transitions (EMT). In addition, several intracellular proteins have been shown to interact with the TGF-β receptor complex, including SARA (19) , FKBP12 (20) , STRAP (21) , TRIP-1 (22) and chimeric tyrosine kinase ETV6-NTRK3 (23) , to facilitate or suppress TGF-β signaling.
Gaithersburg, Maryland). After a12-hour incubation, cells were transferred to fresh medium, and were further cultured for 24 hours.
Virus production and transduction
A DNA fragment corresponding to the wild type TβRII containing HA sequence was subcloned into lentiviral vector pWPI (kindly provided by Dr. Didier Trono, Global Health Institute, Lausanne, Switzerland). To introduce the human Coxsackie Adenovirus Receptor (hCAR) to the B cell lymphoma cell line, pHRCMV/hCAR-EGFP (generously provide by Dr. Mikko Mättö, University of Kuopio, Finland) was used. Lentiviral production with pWPI/HA-TβRII and pHRCMV/hCAR-EGFP, using the envelope vector pMD.G and the packaging vector pCMVR8.91 (kindly provided by Dr. Didier Trono) were carried out as described before (34) . RL cells were seeded in a 12 well plate at 1×10 6 
RESULTS

Rapid loss of TGF-β signaling accounts for the resistance of RL cells to TGF-β-mediated growth suppression
We have shown previously that a B cell lymphoma cell line RL is unresponsive to TGF-β-mediated growth suppression, whereas in the presence of a low dose of PMA, RL cells can be rendered responsive to TGF-β by up-regulating p21 CIP/WAF1 and down-regulating c-Myc (Fig. 1A & B) (13, 35) . RL cells can also be rendered responsive to TGF-β with regards to the growth suppression and up-regulation of p21 CIP/WAF1 by biologically relevant stimulation delivered by anti-IgM treatment ( Fig. 1C & D) . To understand the mechanism behind the lack of TGF-β responsiveness, RL cells were treated with TGF-β in the presence or absence of PMA for various time periods, and the TGF-β signaling was monitored by the nuclear translocation of phospho-Smad2. As shown in Fig. 1E , although RL cells had all the components of the TGF-β pathway, the TGF-β signaling was short lived. The levels of nuclear phospho-Smad2 were decreased by 12 hours and were further down-regulated by 24 hours after TGF-β treatment. By contrast, in the presence of low dose PMA, TGF-β signaling was sustained at 24 hours and growth inhibition was observed. These data suggested that the transient TGF-β signaling might be responsible for the unresponsiveness of RL cells to TGF-β.
TGF-β1-induced down-regulation of TβRII was responsible for transient TGF-β1 signaling in RL cells
To explore whether ligand-induced down-regulation of TGF-β receptors (TβRs) accounts for the transient signaling, we examined the status of TβRI and TβRII upon treatment with TGF-β1 in the presence or absence of PMA for various time periods. As shown in Fig. 2A (Upper panel), TGF-β1 alone induced down-regulation of TβRII at 24 hours, whereas in the presence of PMA, TβRII levels were sustained for at least 48 hours. In contrast, the levels of TβRI were unchanged throughout the time points 12 tested. To determine the status of the cell surface TβRI and TβRII, protein biotinylation was used according to the procedure described by Liu et al. (29) . As shown in Fig. 2A (lower panel), cell surface expression of TβRII was also down-regulated upon TGF-β1 stimulation and the down-regulation was prevented by the PMA treatment. Like the total TβRI level, cell surface TβRI was unaffected by the TGF-β treatment in the presence or absence of PMA. Cell surface status of TβRII was also examined by fluorochrome-conjugated anti-TβRII antibody and analyzed by fluorescence activated cell sorter (FACS) (Supplemental Fig. 1A ). TGF-β1-induced down-regulation of TβRII, both total and cell surface, was also blocked by the proteasome inhibitor MG132 (Fig. 2B , and Supplemental Fig. 1B ). This stability of TβRII along with the stability of Smad2 by MG132 (data not shown; (36) ) resulted in the sustained phosphorylation of Smad2 upon TGF-β1 treatment (Fig. 2C ). To verify further whether ligand-induced down-regulation of TβRII was responsible for transient TGF-β1 signaling, we generated RL cells stably over-expressing HA-tagged TβRII (Supplemental Fig. 2 ). As shown in Fig. 2D , RL cells over-expressing
TβRII were rendered responsive to TGF-β1-mediated growth suppression, and the growth suppression was correlated with higher surface expression of TβRII, sustained activation of Smad2, and expression of p21 CIP/WAF1 ( Fig. 2E and Supplemental Fig. 3 ). These data suggested that ligand-induced down-regulation of TβRII was responsible for transient TGF-β1 signaling, and this down regulation was prevented by a proteasome inhibitor and PMA treatment.
MEK activation is involved in the stabilization of TβRII
To determine the kinase responsible for PMA-induced TβRII stabilization, we investigated the phosphorylation status of MEK1/2 and ERK1/2. As shown in Fig. 3A , dose-dependent increases in phosphorylation of both MEK1/2 and ERK1/2 were observed upon PMA treatment of RL cells. We did not observe any phosphorylation of PKC, as determined by the phospho-specific (pan) PKC antibody, at the low PMA concentration used here (data not shown). Low dose PMA-induced phosphorylation of MEK1/2 and ERK1/2 correlated with increased total and cell surface TβRII levels in RL cells ( To determine whether the relation between the level of active MEK and TβRII status was unique to cell lines, freshly isolated normal human peripheral blood B cells were pre-treated with U0126 followed by the treatment with TGF-β, and the total and cell surface TβRII levels were analyzed ( CHX treatment resulted in the rapid down-regulation of the basal TβRII levels (lanes 1-5), whereas constitutively active MEK1-induced TβRII levels were sustained for longer periods of time (lanes 6-10).
To calculate the half lives (t 1/2 ) of TβRII in the presence of either wild type or constitutively active MEK1, densitometric analysis of the autoradiographs within the linear range of the films were performed. As shown in Fig. 4D (lower panel), t 1/2 for wild type MEK1 was 64+6.9 minutes, whereas t 1/2 for constitutively active MEK1 was 136+27.7 minutes (p<0.01, n=3). These data indicate that the upregulation of TβRII by active MEK1 was via stabilization of TβRII protein.
Constitutively active MEK1 physically interacts with TβRII
In order to determine whether MEK1 stabilizes TβRII via physical interaction, co-immunoprecipitation was performed using lysates prepared from HEK293A cells co-transfected with FLAG-tagged TβRII and either wild type or constitutively active form of MEK1. As shown in Fig. 5A To determine whether interaction between TβRII and MEK occurs endogenously, RL cells were stimulated with either medium alone or PMA for 24 hours. Cells were then treated with U0126 for different time periods, after which cross-linker was used to monitor the interaction. As shown in Fig. 5D (left panel), anti-TβRII antibody was able to pull down endogenous phospho-MEK1 in absence of U0126. 
